0023, Sub-Basement, Purple Zone, Duke Clinics, 200 Trent Drive, Durham, NC 27710
Radiology, Nuclear Medicine
Current Appointments & Affiliations
Associate Professor of Radiology, Radiology, Nuclear Medicine 2014
Education, Training, & Certifications
B.S. 1975, Purdue University1975
M.S. 1977, Purdue University1977
Duke Appointment History
Assistant Professor of Radiology 2006 - 2014
Instructor, Temporary of Nuclear Medicine in the Department of Radiology 1998 - 1998
Assistant Clinical Professor of Radiology 2004 - 2006
Assistant Professor of Radiology 1998 - 2004
Interests and Expertise
As Director of the Duke Medical Center Radiopharmacy, which is permitted by the North Carolina Board of Pharmacy, I am responsible for the procurement, formulation, quality control testing, and dispensing of all radiopharmaceuticals for diagnostic, therapeutic, and research purposes for use in patients in Duke Hospital. Service accomplishments in the fiscal year 2011-2012 included providing all radiopharmaceuticals used for routine patient care at Duke Medical Center. In addition, the Radiopharmacy service participated in a wide variety of clinical research protocols undertaken by Duke investigators either by consultation regarding the pharmaceutical formulation of research compounds or actually performing these formulations as a specialized service. The major accomplishment over the last several years was to move the Radiopharmacy operation into a new state of the art USP <797> compliant clean room environment. This new lab space is specifically designed to satisfy a wide variety of sterile radiopharmaceutical compounding needs for both routine patient care and clinical research well into the future. My general research interests focus on the development and clinical evaluation of diagnostic and therapeutic radiopharmaceuticals for patient care. Specific research interests focus on the clinical applications of 1.) Carbon C-11, Nitrogen N-13, Oxygen 0-15, and Fluorine F-18 labeled radiopharmaceuticals for Positron Emission Tomography (PET) based molecular imaging and 2.) Radiolabeling antibodies, small molecules, and peptides with Gallium Ga-68 for diagnosis and therapeutic radionuclides for the treatment of human cancers. Finally, I am interested in the development of radiopharmaceutical care models in nuclear medicine to optimize the patient's health-related quality of life and achieve positive clinical outcomes, within realistic economic expenditures.
Petry, Neil. “Licensing and regulatory control: radioactivity and radioactive materials.” Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, American Pharmacists Association (APhA), 2020.
Petry, Neil. “Licensing and regulatory control: radiopharmaceutical oversight.” Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, American Pharmacists Association (APhA), 2020.
Kane, Ari, et al. “Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.” J Nucl Med, vol. 59, no. 11, Nov. 2018, pp. 1708–13. Pubmed, doi:10.2967/jnumed.117.202150.
Nandedkar, Sanjeev D., et al. “Reply.” Muscle Nerve, vol. 58, no. 4, Oct. 2018, pp. E31–32. Pubmed, doi:10.1002/mus.26198.
Kraus, V. B., et al. “Direct in vivo evidence of activated macrophages in human osteoarthritis.” Osteoarthritis Cartilage, vol. 24, no. 9, 2016, pp. 1613–21. Pubmed, doi:10.1016/j.joca.2016.04.010.
Bao, Xuhui, et al. “Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.” Invest New Drugs, vol. 34, no. 2, Apr. 2016, pp. 149–58. Pubmed, doi:10.1007/s10637-015-0318-3.
Chin, Bennett B., et al. “Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.” J Nucl Med, vol. 55, no. 5, May 2014, pp. 765–71. Pubmed, doi:10.2967/jnumed.113.124057.
Barrett, John A., et al. “First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 54, no. 3, Mar. 2013, pp. 380–87. Epmc, doi:10.2967/jnumed.112.111203.
Schwarz, S., et al. “The future of USP monographs for PET drugs.” Journal of Nuclear Medicine, vol. 54, no. 3, 2013, pp. 472–75. Scival, doi:10.2967/jnumed.112.115089.
Cooper, James F., et al. “Alumina Depyrogenates F 18 Fludeoxyglucose Injection during Purification Processes.” Pda Journal of Pharmaceutical Science and Technology, vol. 66, no. 3, May 2012, pp. 214–20. Epmc, doi:10.5731/pdajpst.2012.00860.